Pomerantz LLP Announces Class Action Lawsuit Against Replimune Group, Inc.

Strategic Insights -

Pomerantz LLP has announced a class action lawsuit against Replimune Group, Inc. ("Replimune") regarding potential securities fraud and unlawful business practices. The lawsuit concerns the alleged misrepresentation of the efficacy of RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. Investors who purchased Replimune securities during the Class Period have until September 22, 2025, to ask the Court to appoint them as Lead Plaintiff for the class.

Key Takeaways:

  • Pomerantz LLP has filed a class action lawsuit against Replimune Group, Inc. ("Replimune") in relation to potential securities fraud and unlawful business practices.
  • The lawsuit concerns the alleged misrepresentation of the efficacy of RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma.
  • On July 22, 2025, Replimune issued a press release announcing a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for RP1.
  • The CRL indicated that the FDA is unable to approve the application in its present form due to concerns regarding the IGNYTE trial, including patient population heterogeneity and inadequate trial design.
  • As a result of this news, Replimune's stock price fell $9.52 per share, or 77.24%, to close at $2.81 per share on July 22, 2025.
  • Pomerantz LLP has a long history of fighting for the rights of victims of securities fraud, breaches of fiduciary duty, and corporate misconduct, and has recovered numerous multimillion-dollar damages awards on behalf of class members.

Statistics:

  • The class period for the lawsuit spans from February 2023 to July 22, 2025.
  • The lawsuit concerns the alleged misrepresentation of Replimune's RP1 in combination with nivolumab for the treatment of advanced melanoma.
  • Replimune's stock price fell $9.52 per share, or 77.24%, to close at $2.81 per share on July 22, 2025, resulting in a loss of $9.52 per share.

Sources:

  • "Pomerantz LLP Announces the Filing of a Class Action against Replimune Group, Inc. and Certain of its Officers and/or Directors." (Source: Pomerantz LLP)